B cell non-Hodgkin lymphoma is a typical extrahepatic manifestation frequently associated with hepatitis C virus (HCV) infection. The mechanism by which HCV infection leads to lymphoproliferative disorder remains unclear. Our group established HCV transgenic mice that expressed the full HCV genome in B cells (RzCD19Cre mice). We observed a 25.0% incidence of diffuse large B cell non-Hodgkin lymphomas (22.2% in male and 29.6% in female mice) within 600 days of birth. Interestingly, RzCD19Cre mice with substantially elevated serum-soluble interleukin-2 receptor α-subunit (sIL-2Rα) levels (>1000 pg/mL) developed B cell lymphomas. Another mouse model of lymphoproliferative disorder was established by persistent expression of HCV structural proteins through disruption of interferon regulatory factor-1 ( irf-1 _/_ /CN2 mice). Irf-1 _/_ /CN2 mice showed extremely high incidences of lymphomas and lymphoproliferative disorders. Moreover, these mice showed increased levels of interleukin (IL)-2, IL-10, and Bcl-2 as well as increased Bcl-2 expression, which promoted oncogenic transformation of lymphocytes.
Mendeley helps you to discover research relevant for your work.
CITATION STYLE
Tsukiyama-Kohara, K., Sekiguchi, S., Kasama, Y., Salem, N. E., Machida, K., & Kohara, M. (2011). Hepatitis C Virus-Related Lymphomagenesis in a Mouse Model. ISRN Hematology, 2011, 1–8. https://doi.org/10.5402/2011/167501